Biomatrix's synovial fluid mimic approved
This article was originally published in Clinica
Executive Summary
The FDA has approved Biomatrix' elastoviscous fluid Synvisc for treatment of osteoarthritis of the knee. As a result Biomatrix will receive a $12 million milestone payment from Wyeth-Ayerst Laboratories, which will market and distribute the product in the US.
You may also be interested in...
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.